-
1.发明公开
-
公开(公告)号：EP3740501A1
公开(公告)日：2020-11-25
申请号：EP19741831.2
申请日：2019-01-16
IPC分类号： C07K14/705 , C07K14/54 , C07K14/715 , C07K16/28 , A61K39/395 , A61K45/00
-
3.发明公开
公开(公告)号：EP3079693A1
公开(公告)日：2016-10-19
申请号：EP13899201.1
申请日：2013-12-11
申请人： Nant Holdings IP LLC
发明人： NIAZI, Kayvan , RABIZADEH, Shahrooz , LE NY, Anne-Laure , BUZKO, Oleksandr , GOLOVATO, Justin , SOON-SHIONG, Patrick
IPC分类号： A61K31/437 , A61K31/519 , A61P31/16 , A61P31/12
CPC分类号： A61K31/519
摘要： Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
-
公开(公告)号：EP3933408A1
公开(公告)日：2022-01-05
申请号：EP21192583.9
申请日：2018-05-21
申请人： Nant Holdings IP LLC
IPC分类号： G01N33/68 , G01N33/569 , C07K16/30
摘要： An in vitro method of validating an immune therapy that targets a neoepitope of a tumor of a patient is described. The method comprises the steps of using a synthetic antibody against a tumor- and patient-specific neoepitope to enrich or isolate a cellular component carrying the tumor- and patient-specific neoepitope in a bodily fluid obtained from the patient; exposing the cellular component to a modified immune competent cell that expresses a chimeric protein or is coupled to an antibody, wherein the chimeric protein or antibody has binding specificity against the tumor- and patient-specific neoepitope; and detecting an immune response of the modified immune competent cell.
-
公开(公告)号：EP3735984A1
公开(公告)日：2020-11-11
申请号：EP20179172.0
申请日：2017-05-26
IPC分类号： A61K39/00 , C12N15/86 , C07K14/705 , C07K14/54 , C07K14/715
摘要： In certain embodiments, methods and compositions are provided for generating immune responses against tumor neo-antigens or neo-epitopes. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor neo-antigens and neo-epitopes that allow for vaccinations in individuals with preexisting immunity to adenovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engineered natural killer cells. In some embodiments, the methods and compositions further comprises a nucleic acid encoding for an immunological fusion partner.
-
公开(公告)号：EP3579885A1
公开(公告)日：2019-12-18
申请号：EP18751027.6
申请日：2018-02-08
IPC分类号： A61K48/00 , A61K31/7068 , A61K31/675 , A61K31/513 , A61P35/00
-
公开(公告)号：EP3493836A1
公开(公告)日：2019-06-12
申请号：EP17837603.4
申请日：2017-08-02
-
公开(公告)号：EP3475434A2
公开(公告)日：2019-05-01
申请号：EP17815840.8
申请日：2017-03-23
-
公开(公告)号：EP3463440A1
公开(公告)日：2019-04-10
申请号：EP17803712.3
申请日：2017-05-26
IPC分类号： A61K39/00 , C12N15/86 , C07K14/705
-
公开(公告)号：EP3417289A1
公开(公告)日：2018-12-26
申请号：EP17753857.6
申请日：2017-02-16
CPC分类号： G01N33/505 , G01N33/5011
摘要： Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.021 秒)
